Navigation Links
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
Date:5/22/2009

PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of Prilosec OTC with ADDERALL XR resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters (maximum plasma concentration and area under curve) of active medication were not altered for either VYVANSE or ADDERALL XR when coadministered with Prilosec OTC. This study, which is the first to evaluate the pharmacokinetics of VYVANSE and ADDERALL XR taken alone and with Prilosec OTC 40 mg, was recently presented at the International Congress on Clinical Pharmacy, co-sponsored by the American College of Clinical Pharmacy (ACCP), in Orlando, FL.

"Since its approval for ADHD in adults in 2008, VYVANSE has been an important treatment option for physicians treating adult patients seeking significant ADHD symptom control during their busy day," said Jeffrey Jonas, Senior Vice President of Research & Development for the Specialty Pharmaceuticals business at Shire. "This study is the first to evaluate the impact of a proton pump inhibitor on the amphetamine pharmacokinetics of VYVANSE and ADDERALL XR and further supports that, as a prodrug, VYVANSE does not rely on pH for its absorption or conversion."

Heartburn is a common problem affecting millions of Americans. Prilosec OTC and other proton pump inhibitors
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... open letter to shareholders from President & CEO, ... Dear RXi Shareholders, In the ... posted on certain social media sites seem to ...
(Date:12/22/2014)... 22, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), ... treatment of chronic pain, announced today that the ... a pharmacokinetic and pharmacodynamic study with d-Methadone, the ... Racemic methadone is a long-acting opioid ... and substitution therapy in opioid addiction.  It is ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... 2011 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... breakthrough treatments for human disease, announced today that results ... in patients with non-constipating irritable bowel syndrome (IBS) ... edition of the journal Gastroenterology .  The issue ...
... In a just-released National Minority Quality Forum Issue ... ), Gary Puckrein and Gretchen Wartman examine ... insurers (public and private) as a benefit-management tool to ... more for certain high-cost prescription drugs. The authors remind ...
Cached Medicine Technology:Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 2Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 3Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 Fad ... have changed. The reason why most fad diets have ... temporarily. The problem with fad diets is that, as the ... leaving the dieter uncertain of how to reset the metabolism ... this reason, Diet Doc developed their all-inclusive diet plans ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... Charleston, SC (PRWEB) December 22, 2014 ... Deierlein was joined by Pastor Gordon Cashwell for an ... episode, Deierlein asks Gordon, “Why is it so important ... birthday of Jesus?” Cashwell replies, “We all should respect ... this country was founded on Christian beliefs. That means ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... be as effective as a second medication for as ... not been cured by a single antidepressant medication. ... recently published in the Journal of Clinical Psychiatry, found ... can work as well as administering a second antidepressant ...
... , TUESDAY, Aug. 23 (HealthDay News) -- Accidental ... cancer nurses in the United States, a new study ... state who work in outpatient chemotherapy infusion centers and ... eyes had been exposed to the drugs. In ...
... -- Researchers say boys are becoming physically mature earlier ... reaching sexual maturity about 2.5 months earlier every decade ... reason for earlier maturity for boys, as with girls, ... more favorable for it," demographer Joshua Goldstein, director of ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, ... research investigating injectable drugs to treat psoriasis -- an ... the medications are not linked to higher heart risks. ... complete information from drug makers impeded their ability to ...
... than 1 million patients in North America, results from ... as bacteria, in people genetically predisposed to the disorder. ... colon, is one such condition. The aberrant immune ... small signaling proteins secreted by various cells, including ...
... TUESDAY, Aug. 23 (HealthDay News) -- A test that detects ... likely to raise the risk of invasive cervical cancer, when ... many women than the Pap test alone, a new study ... the HPV test alone appears to be enough, said study ...
Cached Medicine News:Health News:Exercise can substitute effectively as second 'medication' for people with depression 2Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: